Altasciences
6605 Merrill Creek Parkway
Everett
Washington
98203
United States
Tel: 425-407-0121
Fax: 425-407-8601
84 articles about Altasciences
-
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
2/26/2024
Hoth Therapeutics, Inc. announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.
-
Altasciences Appoints New General Manager, Clinical Operations
1/29/2024
Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.
-
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
10/31/2023
Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.
-
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
9/21/2023
Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™).
-
Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s
4/18/2023
Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).
-
Altasciences Expands Strategic Support for Early Drug Development in Europe and Adds Key Employees to Its Preclinical Team in North America
10/14/2022
Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key employees.
-
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
4/11/2022
Alzamend Neuro, Inc. today announced that it contracted with Altasciences Clinical Kansas (“ Altasciences ”) and iResearch Atlanta, LLC (“iResearch”) to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study in patients with mild to moderate Alzheimer’s Disease (“Alzheimer’s”).
-
Dr. Wendell P. Davis Joins Altasciences as Vice President, Pathology
2/7/2022
Altasciences announced the appointment of Dr. Wendell P. Davis, D.V.M., Dipl. ACVP, as Vice President, Pathology, effective February 7, 2022.
-
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee
1/21/2022
Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee.
-
Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform
1/4/2022
Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest.
-
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
12/20/2021
Virpax ® Pharmaceuticals, Inc. signed a clinical trial agreement with Altasciences Company, Inc. for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee.
-
Altasciences Chosen by Respira Technologies, Inc. as Drug Product Manufacturing Partner for the World’s First Inhaled Nicotine Replacement Therapy (NRT)
12/14/2021
Altasciences’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy.
-
Altasciences Expands Ligand Binding Laboratory to Meet High Demand for Bioanalytical Solutions
11/23/2021
Altasciences, a leading drug development solution company, announced the completion of a second expansion of their ligand binding laboratory to meet the high demand for quality bioanalytical services.
-
Two new notable biotech/biopharma acquisitions were reported this week: Athenex has acquired Kuur Therapeutics, while Altasciences has acquired preclinical CRO Calvert Laboratories.
-
Audax Private Equity Completes Sale of Altasciences to Novo Holdings
3/29/2021
Audax Private Equity (“Audax”) today announced that it has successfully completed the previously announced sale of Altasciences to Novo Holdings. Altasciences is a leading, fully-integrated, early drug development services platform, providing the pharmaceutical and biotech industries with a trusted partner for drug development, from preclinical safety testing through clinical proof-of-concept studies.
-
Altasciences Qualifies Quantitative Serological Assay for Detection of SARS-CoV-2 IgG Antibodies
3/17/2021
Altasciences , working with the National Research Council of Canada (NRC), has qualified a quantitative serological assay for the detection of SARS-CoV-2 IgG antibodies, to support vaccine development in studies from discovery to Phase II.
-
Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease
3/12/2021
Altasciences is proud to have conducted preclinical studies for Verve Therapeutics that support the development and advancement of Verve’s gene editing approach to treating cardiovascular diseases. Altasciences’ Seattle team performed intravenous preclinical studies, including supporting analyses of pharmacodynamic markers and whole liver DNA editing
-
Altasciences Doubles Square Footage of their CDMO Facility
3/9/2021
Altasciences, a fully integrated early phase CRO/CDMO has started the expansion of their CDMO facility in Philadelphia, PA. The additional 35,000-square-foot building directly adjoins the current location, and will be fully renovated to meet the growing business needs.
-
Dr. Joseph A. Francisco Appointed Chief Toxicologist at Altasciences
6/22/2020
Altasciences announced today the appointment of Dr. Joseph A. Francisco as Chief Toxicologist, effective June 22, 2020.
-
Dr. Gaetano Morelli Named Chief Medical Officer at Altasciences
6/9/2020
Altasciences announced today the appointment of Dr. Gaetano Morelli as Chief Medical Officer, effective May 14, 2020. Dr. Morelli is a member of the College of Physicians of Québec, Canada, with over 30 years' medical experience and over 20 years' global clinical research background. He joined Altasciences in 2013 as a GI consultant and then signed on with Altasciences in 2017, first as Medical Advisor, then Clinical PI, and now Chief Medic